ANTX
AN2 Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$4.25
+1.67%Oct 23, 2026, 21:00 UTC
AN2 Therapeutics granted inducement equity awards to two newly hired employees, including options to purchase 10,565 shares of its common stock.
Source:Oct 21, 2026, 11:00 UTC
AN2 Therapeutics, Inc. announced that it will present a poster detailing the design of a planned Phase 2 trial of epetraborole in patients with polycythemia vera at the 18th AN2 Therapeutics, Inc..
Source:Sep 16, 2026, 21:33 UTC
AN2 Therapeutics granted inducement equity awards to its newly-appointed Chief Medical Officer Cameron Trenor, consisting of a non-qualified stock option for 233,333 shares and restricted stock units representing 116,6 shares.
Source:Sep 16, 2026, 21:33 UTC
AN2 Therapeutics appointed Cameron Trenor, M.D. as its new Chief Medical Officer.
Source: